Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 07 06 2019
accepted: 15 10 2019
entrez: 28 11 2019
pubmed: 28 11 2019
medline: 3 4 2020
Statut: epublish

Résumé

Cancer cachexia is common in patients with oesophagogastric cancer (OG) and is linked to overall survival (OS). One of the key components of cachexia is anorexia; it is not known whether anorexia impacts on OS and there is no method of routine screening in current practice. Diagnosis relies on patients describing the symptoms, clinicians diagnosing anorexia and acting upon it. Patients with oesophageal/gastroesophageal junction or gastric cancer were assessed using the Functional Assessment of Anorexia Cachexia Therapy Anorexia/Cachexia Subscale (FAACT A/CS). FAACT A/CS includes 12 questions validated previously to diagnose anorexia in patients with cancer. Of the 182 patients included, 69% scored ≤37/48 and were considered to be anorexic; FAACT A/CS was a better predictor of OS in metastatic patients than body mass index or weight loss in the six months prior to cancer diagnosis. The median OS of patients with FAACT A/CS scores of >37 was longer than patients with scores of ≤37 (19.3 months vs 6.7 months, Hazard Ratio [HR] 2.9, 95% Confidence Interval [CI] 1.4-6.0, p<0.0001). Patients with performance status (PS) 0-2 and FAACT A/CS >37 had substantially longer OS than those with PS 0-2 and FAACT A/CS ≤37 (18.7 months vs 7.9 months, HR 2.5 (95% CI 1.2-5.1, P<0.0001). The FAACT A/CS questionnaire allows clinicians to identify patients with anorexia who may benefit from early nutrition interventions. Importantly, this is the first study to show the association between anorexia and survival in patients with metastatic OG cancers. This will form the basis of future interventional studies to improve patient outcomes.

Identifiants

pubmed: 31774822
doi: 10.1371/journal.pone.0224540
pii: PONE-D-19-14596
pmc: PMC6881015
doi:

Banques de données

figshare
['10.6084/m9.figshare.9293483.v1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0224540

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Gastric Cancer. 2019 Jan;22(1):10-22
pubmed: 30276574
Support Care Cancer. 2009 Feb;17(2):129-35
pubmed: 18386071
Ann Oncol. 2014 Aug;25(8):1492-9
pubmed: 24569913
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Gastric Cancer. 2016 Apr;19(2):597-606
pubmed: 25749718
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Cancer. 1988 May 15;61(10):2022-6
pubmed: 2452006
Support Care Cancer. 2016 Feb;24(2):661-666
pubmed: 26160463
J Am Med Dir Assoc. 2010 May;11(4):229-30
pubmed: 20439040
Dis Esophagus. 2018 Aug 1;31(8):
pubmed: 29846548
Oncotarget. 2017 Aug 10;8(45):79884-79896
pubmed: 29108370
J Clin Oncol. 2015 Jan 1;33(1):90-9
pubmed: 25422490
Crit Rev Oncol Hematol. 2011 Oct;80(1):114-44
pubmed: 21216616
BMJ Support Palliat Care. 2018 Sep;8(3):258-265
pubmed: 29440149
Qual Life Res. 2000;9(10):1137-46
pubmed: 11401046
PLoS One. 2014 Feb 28;9(2):e88553
pubmed: 24586342
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
Dis Esophagus. 2017 Sep 1;30(9):1-7
pubmed: 28859366
Lancet Oncol. 2016 Apr;17(4):519-531
pubmed: 26906526
Ann Oncol. 2014 Aug;25(8):1635-42
pubmed: 24562443
Eur J Cancer. 1998 Mar;34(4):503-9
pubmed: 9713300

Auteurs

Marc Abraham (M)

Department of Nutrition & Dietetics, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Zoe Kordatou (Z)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Jorge Barriuso (J)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Angela Lamarca (A)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Jamie M J Weaver (JMJ)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Claudia Cipriano (C)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

George Papaxoinis (G)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Alison Backen (A)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Wasat Mansoor (W)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH